GlaxoSmithKline plc's (LON: GSK) majority-owned ViiV Healthcare has seen positive results from two Phase III studies investigating its two-drug HIV treatment, Proactive Investors reported on Thursday.

The current standard treatment involves a three-drug regimen of dolutegravir and two nucleoside reverse transcriptase inhibitors.

However, results from the GEMINI-1 and GEMINI-2 studies show a two-drug regimen of dolutegravir and lamivudine is just as effective.

The studies were designed to evaluate the safety and efficacy of the two-drug regimen compared to the standard three-drug regimen. Both GEMINI-1 and GEMINI-2 met their primary endpoint for non-inferiority, a standard measure of HIV control, at Week 48.

ViiV plans to submit for regulatory approval for the two-drug regimen later this year. Full results from the studies will be presented at an upcoming meeting.